Research offers promising insights into the ideal frontline therapies for mantle cell lymphoma (MCL), but there are continued unmet needs in the relapsed/refractory setting, blood cancer specialists ...

• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...

Patients with relapsed/refractory mantle cell lymphoma have experienced event-free survival and overall survival benefits due to advances in second-line treatment approaches over time. Patients with ...

Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center details evolving mantle cell lymphoma care: ECHO acalabrutinib-BR and chemo-free zanubrutinib BOVen triplets challenge standards.

Mantle cell lymphoma (MCL) is rare and difficult to manage, since it can range from a slow-growing disease to an aggressive form that is difficult to control. Fortunately, a new wave of treatments and ...

Mantle cell lymphoma (MCL) is often an aggressive form of cancer traditionally treated with chemotherapy, immunotherapy, and stem cell transplants when appropriate. Emerging therapies may offer more ...

• People with mantle cell lymphoma typically experience alternating periods where cancer symptoms lessen or disappear followed by times when the disease returns, with the average symptom-free interval ...